Please assess the completion status of the following clinical trial:

Trial Title: T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies will be eligible for this trial. -Patients with a life expectancy \>6 weeks~* Patients with a Karnofsky score of \>/= 50~* No severe intercurrent infection.~* Patient, parent/guardian able to give informed consent.~* Patients with bilirubin \<2x normal, SGOT \<3x normal, and Hgb \>8.0~* Patients with a creatinine \<2x normal for age~* Patients should have been off other investigational therapy for one month prior to entry in this study.~Exclusion Criteria:~-Patients with a life expectancy of \<6 weeks. -Patients with a Karnofsky score of \< 50. -Patients with a severe intercurrent infection. -Patient, parent/guardian unable to give informed consent. -Patients with a bilirubin \>2x normal. SGOT \>3x normal or abnormal prothrombin time. -Patients with a creatinine \>2x normal for age -Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom.~Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigators discretion after approval by the CAGT Protocol Review Committee and the FDA reviewer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EBV specific CTL (Type: EXPERIMENTAL): autologous EBV specific CTLs

Based on this trial design, predict the completion outcome and termination type (if applicable).